OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

Beginning on January19, 2018, representatives of Orexigen Therapeutics, Inc. (the “Company”) will begin conducting meetings with investors and others, during which the Company may reference the slides that are attached as Exhibit 99.1 to this Current Report on Form 8-K, which are incorporated herein by reference.

***

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished to Item 7.01 and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to Item 7.01 of this Current Report on Form 8-K.

By filing this Current Report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report. The information contained in this report is intended to be considered in the context of the Company’s filings with the Securities and Exchange Commission (“SEC”) and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

Item 7.01 Financial Statements and Exhibits.

(d)Exhibits.

Orexigen Therapeutics, Inc. Exhibit
EX-99.1 2 d516242dex991.htm EX-99.1 EX-99.1 Progress Report I January 2018 Exhibit 99.1 Forward Looking Statements This presentation contains forward-looking statements about Orexigen Therapeutics,…
To view the full exhibit click here

About OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX)

Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.